Rheumatology, 2-Volume Set, 6th Edition

Rheumatology, 2-Volume Set

6th Edition

By Marc C. Hochberg, MD, MPH, Professor of Medicine and Epidemiology and Preventative Medicine; Head, Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA ; Alan J. Silman, MD, ARC Professor of Rheumatic Disease Epidemiology, Director, ARC Epidemiology Research Unit, University of Manchester, UK; Josef S. Smolen, MD, Professor of Medicine, Chairman, Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna; Chairman, Second Department of Medicine, Center for Rheumatic Diseases, Hietzing Hospital, Vienna, Austria ; Michael E. Weinblatt, MD, John R. and Eileen K. Riedman Professor of Medicine, Harvard Medical School; Division of Rheumatology, Immunology and Allergy, Brigham and Women?s Hospital, Boston, Massachusetts, USA and Michael H. Weisman, MD, Chief, Division of Rheumatology, Professor of Medicine, Cedars-Sinai Medical Center, David Geffen School of Medicine and UCLA, Los Angeles, California, UA

Section 1: The Scientific Basis of Rheumatic Disease

1. Epidemiologic concepts and the classification of rheumatic and musculoskeletal conditions

2. Principles of clinical outcome assessment

3. Principles of health economics and application to rheumatic disorders

4. The synovium

5. The articular cartilage

6. Bone structure and function

7. Tendons and ligaments

8. Connective tissue responses to mechanical stresses

9. Biomechanics of peripheral joints

10. Biomechanics of the spine

11. Principles of genetic epidemiology

12. Principles and techniques in molecular biology

13. Cytokines

14. Signal transduction in immune cells

15. The principles of adaptive immunity

16. Principles of innate immunity

17. Systems biology

18. Epigenetics in Rheumatology

19. The microbiome in rheumatic diseases

20. Tissue destruction and repair

21. Principles of tissue engineering and cell- and gene-based therapy

22. Osteoimmunology

23. Inflammation and its mediators

24. Scientific basis of pain

25. Effects of the neuroendocrine system on development and function of the immune system

26. Interpreting the medical literature for the rheumatologist: study design and levels of evidence

27. Ethics in clinical trials

Section 2: Clinical Basis of Rheumatic Disease

28. History and physical examination

29. Pattern recognition in arthritis

30. Role of laboratory tests in rheumatic disorders

31. Synovial fluid analysis

32. Minimally invasive procedures

33. Skin in rheumatic disease

34. The eye in rheumatic disease

35. The heart in rheumatic disease

36. The lung in rheumatic disease

37. Gastrointestinal tract and rheumatic disease

38. The kidney and rheumatic disease

39. The nervous system in rheumatic disease

Section 3: Evaluation: Imaging Techniques

40. Conventional radiography and computed tomography

41. Functional magnetic resonance imaging

42. Musculoskeletal ultrasound

43. Bone scintigraphy and positron emission tomography

44. Dual x-ray absorptiometry and measurement of bone

45. Use of imaging as an outcome measure in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis in clinical trials

Section 4: Principles of Management

46. Arthritis patient education, health promotion, and team approaches to management

47. Principles of rehabilitation: physical and occupational therapy

48a. Complementary and alternative medicine

48b. Placebos, Caring and Healing in Rheumatology

49. Drug Development

50. Non-pharmacologic pain management

51. Pharmacogenomics in rheumatology

52. Principles of opioid treatment of chronic musculoskeletal pain

53. Non-steroidal anti-inflammatory drugs

54. Systemic glucocorticoids in rheumatology

55. Nonimmunosuppresive disease-modifying antirheumatic drugs

56. Methotrexate

57. Leflunomide

58. Immunosuppressives: cyclosporine, cyclophosphamide, azathioprine, mycophenolate mofetil

59. T-cell costimulation and other directed therapies

60. B-Cell depletion

61. Cytokine neutralizers: interleukin-1 inhibitors

62. Interleukin-6 Inhibition

63. Tumor necrosis factor blocking therapies

64. Kinase inhibition: a new therapeutic principle in rheumatology

65. Emerging therapeutic targets: GM-CSF, IL-17and IL-23

66. Biosimilars in Rheumatology

67. Infections and biologic therapy in rheumatoid arthritis: an update on risk and prevention

68. Drugs and pregnancy

69. Aspiration and injection of joints and periarticular tissues and intralesional therapy

70. Perioperative care of patients with rheumatic disease

Section 5: Regional and Widespread Pain

71. Neck pain

72. Lumbar spine disorders

73. The shoulder

74. The elbow

75. The wrist and hand

76. The hip

77. The knee

78. The ankle and foot

79. The temporomandibular joint

80. Fibromyalgia and related syndrome

81. Entrapment neuropathies and compartment syndromes

82. Complex regional pain syndrome (reflex sympathetic dystrophy)

Section 6: Rheumatoid Arthritis and Other Synovial Disorders

83. Classification and epidemiology of rheumatoid arthritis

84. Preclinical features of rheumatoid arthritis

85. Clinical features of rheumatoid arthritis

86. Extra-articular features of rheumatoid arthritis and systemic involvement

87. Adult-onset Still's disease

88. Imaging of rheumatoid arthritis

89. The contribution of genetic factors to rheumatoid arthritis

90. Animal models of arthritis

91. Autoantibodies in rheumatoid arthritis

92. Cellular immunity in rheumatoid arthritis

93. Angiogenesis and vasculogenesis in rheumatoid arthritis

94. The rheumatoid joint: synovitis and tissue destruction

95. Evaluation and management of early inflammatory polyarthritis

96. Evaluation and outcomes of patients with rheumatoid arthritis

97. Management of rheumatoid arthritis: synovitis

98. Multidisciplinary approach to rheumatoid arthritis

Section 7: Pediatric Rheumatology

99a. Evaluation of musculoskeletal complaints in children: clinical evaluation

99b. Evaluation of musculoskeletal complaints in children: non-inflammatory musculoskeletal disorders

100. Classification and epidemiology of juvenile idiopathic arthritis

101. Clinical Features of juvenile idiopathic arthritis

102. Etiology and pathogenesis of juvenile idiopathic arthritis

103. Management of juvenile idiopathic arthritis

104. The juvenile-onset spondyloarthropathies

105. Connective tissues diseases in children

106. Rehabilitation and psychosocial issues in juvenile idiopathic arthritis

Section 8: Infection-Related Rheumatic Diseases

107. Infectious Arthritis I: bacterial arthritis

108. Infectious Arthritis II: mycobacterium, brucella, fungal, and parasitic arthritis

109. Lyme disease

110. Rheumatologic aspects of viral infections

111. Acute rheumatic fever

112. Reactive arthritis

Section 9: Spondyloarthropathies

113. Classification and epidemiology of spondyloarthritis

114. Clinical features of axial spondylarthritis

115. Etiology, pathogenesis, and pathophysiology of ankylosing spondylitis

116. Genetics of axial spondyloarthritis

117. Imaging of spondyloarthritis

118. Management of ankylosing spondylitis/axial spondyloarthritis

119. Classification and epidemiology of psoriatic arthritis

120. Clinical features of psoriatic arthritis

121. Etiology and pathogenesis of psoriatic arthritis

122. Management of psoriatic arthritis

123. Enthesopathies

Section 10: Connective Tissue Disorders

124. Epidemiology and classification of systemic lupus erythematosus

125. Preclinical features of lupus

126. Clinical features of systemic lupus erythematosus

127. Genetics of lupus

128. Immunopathology of systemic lupus erythematosus

129. Animal models of lupus

130. Autoantibodies in systemic lupus erythematosus

131. Pathogenesis of lupus

132. Drug-induced lupus

133. Assessing disease activity and outcome in systemic lupus erythematosus

134. Management of non-renal/non-central nervous system lupus

135. Treatment of neuropsychiatric lupus

136. Systemic lupus erythematosus: treatment-renal involvement

137. Systemic lupus erythematosus in the pregnant patient and neonatal lupus

138. Sjögren syndrome

139. Antiphospholipid syndrome: overview of pathogensis, diagnosis, and management

140. Classification and epidemiology of scleroderma

141. Assessing disease activity and outcome in systematic sclerosis (scleroderma)

142. Clinical features of systemic sclerosis

143. Etiology and pathogenesis of systemic sclerosis

144. Management of systemic sclerosis

145. Pulmonary management of systemic sclerosis

146. Raynaud's phenomonen

147. Localized scleroderma and scleroderma-like syndromes

148. Clinical features, classification, and epidemiology of inflammatory muscle disease

149. Inflammatory muscle disease-etiology and pathogenesis

150. Management of inflammatory muscle disease

151. Metabolic, drug-induced, and other non-inflammatory myopathies

152. Overlap syndromes

Section 11: The Vasculitides

153. Classification and epidemiology of vasculitis

154. Biology and immunopathogenesis of vasculitis

155. Polyarteritis nodosa and Cogan's Syndrome

156. Polymyalgia rheumatica and giant cell arteritis

157. Antineutrophil cytoplasmic antibody-associated vasculitis

158. Takayasu's arteritis

159. Behçet's syndrome

160. Kawasaki disease

161. Henoch-Schönlein purpura/immunoglobulin-A vasculitis

162. Cutaneous vasculitis and panniculitis

163. Cryoglobulinemia

164. Primary angiitis of the central nervous system

Section 12: Other Systemic Illnesses

165. Monogenic autoinflammatory diseases

166. Sarcoidosis

167. Relapsing polychondritis

168. Amyloidosis

169. Digital clubbing and hypertrophic osteoarthropathy

170. Miscellaneous arthropathies

Section 13: Osteoarthritis and Related Disorders

171. Osteoarthritis: epidemiology and classification

172. Local and systemic risk factors for incidence and progression of osteoarthritis

173. Clinical features of osteoarthritis

174. Animal models of osteoarthritis

175. Pathogenesis and pathology of osteoarthritis

176. Genetics of osteoarthritis

177. Imaging of osteoarthritis

178. Assessment of the patient with osteoarthritis and measurement of outcomes

179. Preclinical osteoarthritis

180. Assessment of imaging outcomes in osteoarthritis

181. Management of osteoarthritis

182. Diffuse idiopathic skeletal hyperostosis

183. Neuropathic arthropathy

184. Osteonecrosis

185. Rare Osteoarthritis: ochronosis and Kashin-Beck disease

Section 14: Crystal-Related Arthropathies

186. Epidemiology of gout

187. Etiology and pathogenesis of gout

188. Clinical gout

189. The management of gout and hyperuricemia

190. Calcium pyrophosphate crystal-associated arthropathy

191. Basic calcium phosphate crystal deposition disease

192. Other crystal-related arthropathies

Section 15: Endocrine and Hemoglobin-Related Arthritis and Storage Diseases

193. Rheumatoid manifestations of endocrine and lipid disease

194. Hemophilia and von Willebrand disease

195. Joint and bone lesions in hemoglobinopathies

196. Hemochromatosis

Section 16: Metabolic Bone Disease

197. Epidemiology and classification of osteoporosis

198. Clinical features of osteoporosis

199. Pathogenesis of osteoporosis

200. Biochemical markers in bone disease

201. Management of osteoporosis

202. Glucocorticoid-induced osteoporosis

203. Osteomalacia and rickets

204. Primary hyperparathyroidism: rheumatologic manifestations and bone disease

205. Renal osteodystrophy

206. Paget disease of bone

Section 17: Heritable Disease and Tumors of Bone and Connective Tissue

207. Gaucher disease

208. Mucopolysaccharidoses

209. Heritable connective tissue disorders

210. Hypermobility syndrome

211. Skeletal dysplasias

212. Bone tumors